2019-2025 Global and China Marijuana Market Latest Innovations – Cara Therapeutics, Cannabis …

… GreenGro Technologies, GW Pharmaceuticals, Lexaria Corp, MMJ America, Medicine Man, Canopy Growth, Aphria, Aurora Cannabis Inc., mCig Inc …

Researchstore.biz recently disclosed a new report titled Global and China Marijuana Market Research by Company, Type & Application 2013-2025 which states that the industry will grow with significant CAGR over the period between 2018 and 2025. The report has included various parameters on which the Marijuana market is analyzed such as the product, applications, regions, competition, and many others. It forbye performs the deep study of price, demand-supply, technology, and factors related to the market growth of trade. The global market report is prepared to keep in mind the key requirements of the customer, which is to empower them with the information to take on the market. It covers the prevailing marketplace length of the market and its development rates from 2013 to 2025 along with profiles of the major players in the market.

Key players/manufacturers of this market report: Cara Therapeutics, Cannabis Sativa, CannaGrow Holdings, United Cannabis, Growblox Sciences, GreenGro Technologies, GW Pharmaceuticals, Lexaria Corp, MMJ America, Medicine Man, Canopy Growth, Aphria, Aurora Cannabis Inc., mCig Inc,

DOWNLOAD FREE SAMPLE REPORT: https://researchstore.biz/report/global-and-china-marijuana-market/78062/#requestforsample

The features of the report include market characteristics, segmentation, regional breakdowns, market size and shares, competitive landscape, and trends and strategies. The Marijuana market is split by product type with production cost, sales revenue, demand, and supply strategy as well as on the basis of the end user with consumption, the study of past and future prospects of the market share, and the CAGR structure.

Geographical regional data will help you in targeting all the best-performing regions. The industry research is scattered over the world which includes the market in Asia-Pacific, North America, Europe, South America, Middle East & Africa

Breakdown data by product type a with consumption (sales), market share and growth rate for each application, covers: Industrial Grade, Pharmaceutical Grade,

Breakdown data by application with consumption (sales), market share and growth rate for each application, covers: Chronic Pain, Arthritis, Migraine, Cancer, Others,

The report further stresses the probable risks associated with various opportunities in the Marijuana market and also provides gives a clear and precise market overview combining statistics and estimates. It enables readers to engulf the qualitative information of forthcoming challenges, threats, limitations as well as changing dynamic factors, consumption concerning prospects, and growth trends using which current market players and novices could make informed business decisions and built effective market stratagems.

ACCESS FULL REPORT: https://researchstore.biz/report/global-and-china-marijuana-market/78062/

The research will bring equal status for both the existing giants as well as the new entrees by producing value for level playing competition. Additionally, the report studies Marijuana market scope, production volume, consumption ratio, potential buyers market presence, and cost analysis. The key segments coupled with their market forecasts both in terms of revenue and volume have been added to the market research study. This report will raise the knowledge of the overall outlook of the entire market. The authors have proposed a profound elucidation which has been gathered from various primary and secondary information sources.

Customization of the Report:This report can be customized to meet the client’s requirements. Please connect with our sales team (sales@researchstore.biz), who will ensure that you get a report that suits your needs.

Related Posts:

  • No Related Posts

Reviewing Endo International plc (ENDP)’s and Aurora Cannabis Inc. (NYSE:ACB)’s results.

As Drug Manufacturers – Other companies, Endo International plc (NASDAQ:ENDP) and Aurora Cannabis Inc. (NYSE:ACB) are our subject to contrast …

As Drug Manufacturers – Other companies, Endo International plc (NASDAQ:ENDP) and Aurora Cannabis Inc. (NYSE:ACB) are our subject to contrast. And more specifically their risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Endo International plc 2.93B 0.74 967.87M -4.49 0.00
Aurora Cannabis Inc. N/A 0.00 N/A 0.22 26.53

We can see in table 1 the earnings per share, top-line revenue and valuation of Endo International plc and Aurora Cannabis Inc..

Profitability

Table 2 has Endo International plc and Aurora Cannabis Inc.’s net margins, return on equity (ROE) and return on assets.

Net Margins Return on Equity Return on Assets
Endo International plc -33.03% 0% -10.1%
Aurora Cannabis Inc. 0.00% 0% 0%

Analyst Recommendations

In next table is delivered Endo International plc and Aurora Cannabis Inc.’s ratings and recommmendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Endo International plc 0 6 4 2.40
Aurora Cannabis Inc. 0 0 0 0.00

The average price target of Endo International plc is $16.89, with potential upside of 74.12%.

Institutional and Insider Ownership

Endo International plc and Aurora Cannabis Inc. has shares held by institutional investors as follows: 0% and 5.77%. Endo International plc’s share held by insiders are 0.7%. Comparatively, Aurora Cannabis Inc. has 3.09% of it’s share held by insiders.

Summary

On 5 of the 9 factors Aurora Cannabis Inc. beats Endo International plc.

Endo International plc develops, manufactures, and distributes pharmaceutical products and devices worldwide. Its U.S. Generic Pharmaceuticals segment provides tablets, capsules, powders, injectables, liquids, nasal sprays, ophthalmics, and transdermal patches for pain management, urology, central nervous system disorders, immunosuppression, oncology, womenÂ’s health, and cardiovascular disease markets. The companyÂ’s U.S. Branded Pharmaceuticals segment offers pain management products, such as Lidoderm, OPAN ER, Percocet, and Voltare Gel. This segment also provides Supprelin LA for central precocious puberty treatment; XIAFLEX for treating PeyronieÂ’s and DupuytrenÂ’s contracture diseases; Fortesta Gel for hypogonadism treatment; Testim Gel for the treatment of endogenous testosterone; Frova for migraine headaches; Valstar, a sterile solution for intravesical instillation of valrubicin; Vantas for the palliative treatment of advanced prostate cancer; Aveed for the treatment of low testosterone; TESTOPEL, a long-acting implantable pellet; and NASCOBAL, a nasal spray. Its International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas, including attention deficit hyperactivity disorder, pain, womenÂ’s health, and oncology; generic, branded generic, and over-the-counter products in the areas of dermatology and anti-infectives; and healthcare services, products, and solutions to hospitals, pharmacies, and practitioners, as well as for government healthcare programs. The company also provides injectables for the treatment of pain, anti-infectives, cardiovascular, and other therapeutics areas. It sells its branded pharmaceuticals and generics directly, as well as through wholesale drug distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.

Aurora Cannabis Inc. produces and distributes medical cannabis products. It is vertically integrated and horizontally diversified across various segments of the cannabis value chain, from facility engineering and design to cannabis breeding, genetics research, production, derivatives, high value-add product development, home cultivation, wholesale, and retail distribution. The company’s products consist of dried cannabis and cannabis oil; CanniMed vegan capsules; and hemp products, as well as sells vaporizers, consumable vaporizer accessories, and herb mills for using herbal cannabis products. It also operates CanvasRX, a network of cannabis counseling and outreach centers; and provides cannabis analytical product testing services. The company has operations in 19 countries across five continents. Aurora Cannabis Inc. has collaboration agreements with PharmaChoice, Pharmasave, and Shoppers Drug Mart for the distribution, sale, and marketing of medical cannabis products through their respective networks of pharmacies. The company has a strategic agreements with Hempco Food and Fiber Inc.; CTT Pharmaceuticals Inc.; Choom Holdings Inc.; Capcium Inc.; The Green Organic Dutchman Holdings Ltd.; Société des Alcools du Québec; Alcanna; Radient Technologies; Micron Waste; Wagner Dimas; Evio; and Cann Group Limited. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Related Posts:

  • No Related Posts

As of February, 14 Analysts See $-0.04 EPS for Aurora Cannabis Inc. (ACB)

Aurora Cannabis Inc. (TSE:ACB)’s quarterly earnings will be revealed on February, 14., RTT reports. Analysts forecast 300.00 % diference or $-0.04 …

Aurora Cannabis Inc. (TSE:ACB)’s quarterly earnings will be revealed on February, 14., RTT reports. Analysts forecast 300.00 % diference or $-0.04 from the $0.02 EPS from 2018. Analysts at Wall Street see Aurora Cannabis Inc.’s -133.33 % negative EPS growth compared to $0.12 EPS for previous quarter. ACB is reaching $8.4 during the last trading session, after decreased 1.52%.Currently Aurora Cannabis Inc. is after 0.00% change in last January 22, 2018. ACB has also 7.49 million shares volume. The stock the S&P500 by 0.00%.

Aurora Cannabis Inc., together with its subsidiaries, produces and distributes medical marijuana products in Canada.The firm is worth $8.38 billion. The company’s products consist of dried cannabis and cannabis oil.The P/E ratio is 29.27. It also operates as a pharmaceutical wholesaler and narcotics dealer of medical marijuana in Germany and the European Union; and produces and sells proprietary systems for the indoor cultivation of cannabis, organic microgreens, vegetables, and herbs.

For more Aurora Cannabis Inc. (TSE:ACB) news brought out recently go to: Midasletter.com, Stockhouse.com, Investorplace.com, Midasletter.com or Midasletter.com. The titles are as follows: “Canopy Growth Corp (TSE:WEED) Surge: Benjamin A. Smith Called This Market Move – Midas Letter” brought out on January 15, 2019, “Generating Cash Flow from Cannabis Waste-C.MWM-T.ACB-P.CANNABIS – Stockhouse” on January 17, 2019, “3 Strikes Against Aurora Stock and Why You Can Ignore Them – Investorplace.com” with a publish date: December 31, 2018, “VIDEO: Campaign for Cannabis Amnesty on Aurora Cannabis Inc (TSE:ACB) Support – Midas Letter” and the last “Aurora Cannabis Inc (TSE:ACB) Strategic Wager: Dilute Now To Establish Strategic Preeminence – Midas Letter” with publication date: May 14, 2018.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Related Posts:

  • No Related Posts

Is Marijuana Stock KushCo Holdings a Buy?

The best and worst performing of the four largest ones (by market cap), Cronos and Aurora Cannabis, respectively, are shown in the chart below.

Investor interest in marijuana stocks soared last year, thanks largely to several huge events, including cannabis becoming legal for recreational use in California (January) and Canada (October).

We’re going to examine KushCo Holdings(NASDAQOTH:KSHB) — which provides packaging solutions and other ancillary products and services to the legal cannabis industry — to see whether its stock is a buy.

Several marijuana products in various packaging, including buds, oil, and rolls.

Image source: Getty Images.

Stock performance: The short and longer term

One of the first things a potential investor in KushCo probably wants to know is how the stock has performed over the short and longer terms, including how it’s stacked up against other cannabis stocks.

A one-year loser

KushCo stock declined 18.6% over the one-year period through Friday, Jan. 18. By comparison, the S&P 500 (including dividends) edged down 2.7%.

The stocks of the Canadian marijuana growers are a mixed bag over this same period. The best and worst performing of the four largest ones (by market cap), Cronos and Aurora Cannabis, respectively, are shown in the chart below. (Tilray is actually the best performer of the larger players, but it’s only been traded in the U.S. since July.) Shares of ancillary cannabis companies Innovative Industrial Properties(NYSE:IIPR) and EnWave have performed wonderfully and solidly, respectively. Innovative Industrial Properties (IIP) is a San Diego-based, cannabis-focused real estate investment trust that’s profitable and pays a dividend yielding 2.6%; EnWave is a Canadian company that launched its dehydration technology into the cannabis industry last year.

KSHB Total Return Price Chart

Data by YCharts.

A winner since its IPO three years ago

Since its initial public offering in early January 2016, KushCo stock has surged 171% — more than four times the S&P 500’s 40.9% return. Aurora Cannabis has rocketed 1,370% higher over this period, while EnWave has gained 90.2%. (However, EnWave only became a “cannabis stock” last year.) Cronos and IIP aren’t shown because they have not traded in the U.S. (not traded, period, for IIP) for this entire period.

KSHB Total Return Price Chart

Data by YCharts.

KushCo’s business

KushCo Holdings, which is based in California, was founded in 2010 by Nick Kovacevich, the company’s CEO and chairman of the board, and Dallas Imbimbo, who serves on the board. The company started life as Kush Bottles and changed its name last year to reflect its expansion beyond its packaging roots. It’s very close to a pure play, with only its acquired creative-design business having clients outside the cannabis realm. In short, the company’s aim is to be a one-stop shop for customers.

KushCo has sales and distribution facilities across the U.S. and Canada, and opened an office in China last fall.

KushCo’s businesses include:

  • Kush Supply: The largest distributor in the U.S. of vaporizer products, packaging, supplies, and accessories to cannabis growers, processors, extractors, manufacturers, and retailers.
  • Kush Energy: Provider of pure hydrocarbon gases and solvents to the cannabis sector. These products are used to produce cannabis extracts, such as hemp-derived cannabidiol (CBD) oils. So this business should benefit from the December passage of the Farm Bill, which legalized hemp across the U.S. effective Jan. 1, 2019. (CBD is a nonpsychoactive chemical found in the cannabis plant that has been linked to various wellness benefits.)
  • The Hybrid Creative: A creative design agency providing services for cannabis and noncannabis brands.
  • Koleto: The company’s research and development arm.

KushCo’s leadership

As previously noted, Kovacevich leads the company. It’s generally a plus to have a founder running the business, since these folks know their companies intimately, and often have much skin in the game. Studies suggest that founder-led companies outperform in the stock market.

Kovacevich owned 11,035,000 KushCo shares, valued at about $59.9 million based on the closing price of $5.43 per share, as of his most recently reported transaction on Jan. 8. (This was a sale at prices ranging from $5.98 to $6.15 per share for a total of $1.21 million.) Kovacevich has a 13.8% stake in the company, with Imbimbo not far behind at about 13%.

KushCo’s financial performance

Like many in the sector, KushCo has revenue that’s been increasing rapidly, while its losses on both an operational and a net basis have been growing. The company is rapidly scaling up its business and investing to fuel long-term growth.

KSHB Revenue (TTM) Chart

Data by YCharts.

KushCo’s gross and operating margins have declined rather sharply since late 2017. Investors shouldn’t be overly concerned with operating margin at this point, given that the company is opening new facilities and otherwise spending to fuel long-term growth. (Operating margin will at least partly improve along with an improvement in gross margin.) But gross margin (total revenue minus cost of goods sold, divided by total revenue) is another matter.

In its fiscal Q1 earnings release, the company addressed this issue: “While we are confident in the Company’s upward trajectory, we acknowledge the impact that our dramatic growth has had on our gross margins, in particular, the utilization of air freight and additional cost incurring quality control measures at our receiving warehouse to meet demand. We have implemented a number of strategic operational initiatives that will drive our gross margins back toward 30% as we scale the business, with improvements in margins expected in the second half of fiscal 2019.”

KSHB Gross Profit Margin (Quarterly) Chart

Data by YCharts.

As to valuation, KushCo stock’s price-to-sales (P/S) ratio is 5.6, which is quite high in general, but reasonable relative to other cannabis stocks.

KSHB PS Ratio (TTM) Chart

Data by YCharts.

Investors need to keep an eye on liquidity and shareholder dilution. At the end of its most recently reported quarter, KushCo had cash and equivalents of just over $3 million and long-term debt of $7.2 million on its balance sheet. The company burned through $48 million in cash over the last year, financing its ramped-up spending through increasing its debt load and issuing significantly more shares of stock. (Over the last one and two years, the number of shares has increased about 27% and 62%, respectively.) Increasing the number of shares of stock has a dilutive effect on the ownership stakes of existing shareholders.

KSHB Cash and Equivalents (Quarterly) Chart

Data by YCharts.

Canopy Growth set to become the ‘global titan’ of cannabis: CIBC report

Canopy Growth Corp. in Smiths Falls is poised to dominate the global … And as the largest and most well-known cannabis company in the world, …

Canopy Growth Corp. in Smiths Falls is poised to dominate the global cannabis industry, a new report says.

The CIBC World Markets report compares the cannabis industry to both the gold rush and the development of the internet and the automobile. Only a few companies will live up to the “lofty expectations” of many and dominate the global market, said the report from the investment banking arm of the Canadian Imperial Bank of Commerce.

“We believe that Canopy Growth represents the industry’s best chance at a global titan.”

Canopy has billions in the bank, superior management, the potential to make breakthroughs with new medical products, and global aspirations, said the report. And as the largest and most well-known cannabis company in the world, Canopy also has a head start on global competitors.

“Investors rarely get to witness the birth of an industry,” said the report. While dozens of small and medium-size cannabis firms will earn moderate revenues, only a handful will dominate the global trade, the report predicts.

The report named Cronos Group as another likely winner. Cronos owns cannabis growing facilities in Ontario and British Columbia, and has international operations.

Canopy and Cronos stand out primarily because of their “best in class” management teams, said the report.

That’s a key factor in an industry in which stock prices ride a roller-coaster.

Prices fluctuate in response to news reports and regulatory changes. Consider Ontario’s rough start to the legalization of recreational cannabis on Oct. 17, with complaints of poor service and delayed deliveries at the online government store. Most Canadian cannabis growers lost 30 to 40 per cent of their company value in a week, the report noted.

On the other hand, even rumours of major players from other industries investing in cannabis can send stocks soaring.

Canopy had a market value of $19.8 billion at the end of the day Monday.

But such valuations matter less for cannabis companies than some other industries, the report said.

“The key element of any investor’s choice is management’s vision for the future, both for the industry as a whole and their own niche within the industry.”

Canopy’s Bruce Linton is probably the most famous cannabis CEO, said the report. That matters because of his familiarity to regulators and ability to negotiate with executives in other industries, it said.

Bruce Linton, founder, CEO and Chairman of Canopy Growth, travels from Ottawa to St. John’s, N.L. on the eve of legalization of pot in Canada to sell the first gram of legal pot from his Tweed store.Julie Oliver / Postmedia

The report said it’s not surprising that Canopy and Cronos have captured the two largest investments in the cannabis industry, from Big Alcohol and Big Tobacco.

Constellation Brands, a U.S. beer, wine and spirits company, poured $5.2 billion into Canopy to develop cannabis beverages. Tobacco giant Altria Group Inc. has a proposed investment in Cronos of $2.4 billion that will be voted on by shareholders next month.

Canopy, which began life as Tweed Marijuana in the old chocolate factory in Smiths Falls, has been the main ambassador for the cannabis industry, said the CIBC report.

The Hershey Canada Chocolate factory in 2007, shortly before closing.Mike Carroccetto / CNSPICS OTT

Canopy has been snapping up other companies at a rapid clip and expanding internationally.

It started by growing marijuana for medical patients and branched into recreational cannabis. Sometime this year, Canopy will unveil cannabis drinks, which officials promise will offer low-calorie, no hangover, healthier alternatives to alcohol.

However, the company still retains a strong focus on medical cannabis, where officials see global opportunity and the potential to replace pharmaceuticals and other products now used for sleep aids, pain treatment and mood therapy.

Canopy is also developing CBD products to treat anxiety in pets, another potentially huge market. (CBD is a non-psychoactive chemical found in cannabis and hemp.)

Staff work in a marijuana grow room at Canopy Growths Tweed facility in Smiths Falls, Ontario on Thursday, Aug. 23, 2018.Sean Kilpatrick / THE CANADIAN PRESS

Canopy Growth Corporation — by the numbers

2,500: Full-time employees

4.3 million: Square feet of Health Canada-licensed production space, spread over 13 facilities across the country that grow and process cannabis

15: Bricks-and-mortar Tweed or Tokyo Smoke stores the company operates in Newfoundland, Saskatchewan and Manitoba that sell recreational cannabis

$5.2 billion: Investment made into Canopy by Constellation Brands, the huge U.S. spirits, beer and wine company. Constellation Brands now owns 38 per cent of Canopy.

15: Countries in which Canopy has operations, partnerships, subsidiaries or business activities: Canada, U.S., Germany, United Kingdom, Colombia, Brazil, Australia, Chile, Denmark, Jamaica, Lesotho, Czech Republic, Spain, Poland and Peru.

$19.8 billion: Market value of Canopy Growth Corp. as of Monday

15: Approximate number of clinical trials Canopy has underway or planned to explore the potential medicinal benefits of cannabis

*sources: CIBC World Market, Canopy Growth Corp., Bloomberg

jmiller@postmedia.com

twitter.com/JacquieAMiller


ALSO IN THE NEWS:

Ottawa’s ‘tired’ ByWard Market building requires more than $1M in short-term repairs

Ottawa is good. According to this public space guru, that’s the problem

Police arrest two men on firearm-related charges after collision


Related Posts:

  • No Related Posts